Vertaling van "other forms " (Nederlands → Frans) :

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Gleevec/Glivec (USD 3.7 billion, +15% lc), a targeted therapy for certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), sustained solid double-digit growth in 2008 based on strong clinical data and its status as the leading therapy for these and other life-threatening forms of cancer.
Glivec/Gleevec (USD 3,7 milliards, +15% en m. l.), traitement ciblé contre certaines formes de leucémie myéloïde chronique (LMC) et les tumeurs stromales gastro-intestinales (GIST), a conservé une croissance soutenue à deux chiffres, grâce à d’excellents résultats cliniques et à son statut de traitement de pointe pour ces maladies et d’autres formes de cancer souvent fatales.

(Power 2007) Power J, French R, Cowan F. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other
(Power 2007) Power J, French R, Cowan F. Subdermal implantable contraceptives versus other forms of reversible

Studies are ongoing in other diseases in which IL-1 beta plays an important role, such as some forms of gout – one of the most painful types of arthritis, COPD (Chronic Obstructive Pulmonary Disease), type 2 diabetes and systemic juvenile idiopathic arthritis.
Les études continuent dans d’autres maladies dans lesquelles IL-1 bêta joue un rôle important, telles que certaines formes de goutte, l’un des types d’arthrite les plus douloureux, la broncho-pneumopathie chronique obstructive (BPCO), le diabète de type 2 et l’arthrite idiopathique juvénile systémique.

Extavia, the Novartis-branded version of Betaferon ® /Betaseron ® for relapsing forms of multiple sclerosis, was launched in the US in 2009, and since then has been approved in over 20 other countries.
Extavia, la marque de Novartis de la version de Betaferon ® /Betaseron ® contre les formes cycliques de la sclérose en plaques (SP), a été lancé en 2009 aux Etats-Unis et a été homologué depuis dans plus de vingt autres pays en 2010.

Extavia, the Novartis-branded version of Betaferon ® /Betaseron ® for relapsing forms of multiple sclerosis, was launched in the US in 2009, and in over 20 other countries, including Canada and Russia, in 2010.
Extavia, la marque de Novartis de la version de Betaferon ® /Betaseron ® contre les formes cycliques de la sclérose en plaques (SP), a été lancé en 2009 aux Etats-Unis et dans plus de vingt autres pays en 2010, dont le Canada et la Russie.

Extavia (USD 49 million), for relapsing forms of multiple sclerosis (MS), was launched in 2009 in the US and more than 20 other countries, marking the entry of Novartis into the field of MS.
Extavia (USD 49 millions), pour les formes cycliques de la sclérose en plaques (SP), a été lancé en 2009 aux Etats-Unis et dans plus de vingt autres pays, marquant l’entrée de Novartis dans ce domaine thérapeutique.

Transversality, co-operation across sectors, consultations concerning the patient and other forms of care sharing are new notions that receive too little support from the NISII.
La transversalité, la collaboration transsectorielle, la concertation autour du patient et d’autres formes de care-sharing sont des notions nouvelles trop peu soutenues par l’INAMI.

Data from the “sentinel general practitioners” (Scientific Institute of Public Health). Sentinel general practitioners form a network of general practitioners who are responsible to the various communities and register medical data including, amongst other things, suicides and attempted suicides.
Les médecins vigies constituent un réseau de médecins généralistes, dépendant des différentes communautés, qui enregistrent des données médicales dont, entre autres, les suicides et tentatives de suicide.

Studies are underway in other disease areas believed to involve IL-1 beta, including some forms of gout, Systemic Juvenile Idiopathic Arthritis (SJIA), Chronic Obstructive Pulmonary Disease (COPD) and type 2 diabetes.
Des études sont en cours pour d’autres maladies qui pourraient impliquer IL-1 bêta, notamment certaines formes de goutte, l’arthrite idiopathique juvénile systémique (AIJS), la broncho-pneumopathie chronique obstructive (BPCO) et le diabète de type.